{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:09:21Z","timestamp":1783904961207,"version":"3.55.0"},"reference-count":60,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The psychiatric and other CNS disorders are characterized with unregulated neuro-inflammatory processes and chronic microglia cell activation resulting with detrimental effect. ABCB1gene polymorphismsC1236T, G2677T\/Aand C3435T are associated with P-glycoprotein expression and function andare linked with predisposition to psychiatric disorders such as schizophrenia and bipolar disorders. The relationship between mood disorders and glucocorticoids has been confirmed and ABCB1 SNPs influence the glucocorticoids access to the brain.<\/jats:p>\n                  <jats:p>The aim of the study is evaluation of the influence of the three most common ABCB1SNPs on predisposition to psychiatric disorders in Macedonian population.<\/jats:p>\n                  <jats:p>In the study 107 unrelated healthy Macedonians of both sexes were enrolled as a control group and patient population of 54 patients (22 to 65 years old) diagnosed with schizophrenia or bipolar disorder. ABCB1 for three polymorphisms were analyzed by Real-Time PCR in both groups.<\/jats:p>\n                  <jats:p>The results have confirmed the role of the ABCB1 gene in predisposition to psychiatric disorders and increased risk of developing bipolar disorder in carriers of the heterozygotes and mutant homozygotes for polymorphic variations in 1236 and 2677 in comparison to the normal genotype carriers. Three-fold higher risk was estimated for psychiatric illness in women that are 1236 and 2677 heterozygous carrier (heterozygous and mutant homozygous) compared to healthy control (men and women) population and four-fold higher risk in comparison only to healthy women population. Mutant allele carriers for 1236 and 2677 polymorphisms that are 35 years and below in patients population have almost three-fold higher risk for development of psychiatric illness.<\/jats:p>","DOI":"10.2478\/prilozi-2018-0008","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T18:17:53Z","timestamp":1524075473000},"page":"71-88","source":"Crossref","is-referenced-by-count":2,"title":["Evaluation of the Role of ABCB1gene Polymorphic Variants on Psychiatric Disorders Predisposition in Macedonian Population"],"prefix":"10.2478","volume":"38","author":[{"given":"Zorica","family":"Naumovska","sequence":"first","affiliation":[{"name":"Institute for Pharmaceutical Chemistry, Faculty of Pharmacy , University \u201cSs. Cyril and Methodius\u201d , Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra K.","family":"Nestorovska","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical Chemistry, Faculty of Pharmacy , University \u201cSs. Cyril and Methodius\u201d , Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Sterjev","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical Chemistry, Faculty of Pharmacy , University \u201cSs. Cyril and Methodius\u201d , Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Filipce","sequence":"additional","affiliation":[{"name":"University Clinic of Psychiatry, Medical Faculty , University \u201cSs. Cyril and Methodius\u201d , Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Grozdanova","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical Chemistry, Faculty of Pharmacy , University \u201cSs. Cyril and Methodius\u201d , Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Dimovski","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical Chemistry, Faculty of Pharmacy , University \u201cSs. Cyril and Methodius\u201d , Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljubica","family":"Suturkova","sequence":"additional","affiliation":[{"name":"Institute for Pharmaceutical Chemistry, Faculty of Pharmacy , University \u201cSs. Cyril and Methodius\u201d , Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Serafimoski","sequence":"additional","affiliation":[{"name":"The Macedonian Academy of Sciences and Arts\u201d , Skopje , Republic of Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"key":"2026071212052248885_j_prilozi-2018-0008_ref_001_w2aab3b7b8b1b6b1ab1ab1Aa","doi-asserted-by":"crossref","unstructured":"1. Beumer W, Gibney SM, Drexhage RC, Pont-Lezica L, Doorduin J, Klein HC, SteinerJ, Connor TJ, Harkin A, Versnel MA, Drexhage HA. The immune theory of psychiatricdiseases: a key role for activated microglia and circulating monocytes. J Leukoc Biol. 2012 Nov;92(5):959-75.10.1189\/jlb.0212100","DOI":"10.1189\/jlb.0212100"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_002_w2aab3b7b8b1b6b1ab1ab2Aa","doi-asserted-by":"crossref","unstructured":"2. Smith RS, Maes M. The macrophage-T-lymphocyte theory of schizophrenia:additional evidence. Med Hypotheses. 1995 Aug;45(2):135-41.10.1016\/0306-9877(95)90062-4","DOI":"10.1016\/0306-9877(95)90062-4"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_003_w2aab3b7b8b1b6b1ab1ab3Aa","doi-asserted-by":"crossref","unstructured":"3. Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999 Sep 15;46(6):729-39.10.1016\/S0006-3223(99)00147-X","DOI":"10.1016\/S0006-3223(99)00147-X"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_004_w2aab3b7b8b1b6b1ab1ab4Aa","doi-asserted-by":"crossref","unstructured":"4. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC.Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 2009 Nov;50(11):1801-7.10.2967\/jnumed.109.066647","DOI":"10.2967\/jnumed.109.066647"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_005_w2aab3b7b8b1b6b1ab1ab5Aa","doi-asserted-by":"crossref","unstructured":"5. Heckers S, Heinsen H, Geiger B, Beckmann H. Hippocampal neuron number in schizophrenia: a stereological study. Arch Gen Psychiatry. 1991; 48:1002\u20131008.10.1001\/archpsyc.1991.01810350042006","DOI":"10.1001\/archpsyc.1991.01810350042006"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_006_w2aab3b7b8b1b6b1ab1ab6Aa","doi-asserted-by":"crossref","unstructured":"6. Walker MA, Highley JR, Esiri MM, et al. Estimated neuronal populations and volumes of the hippocampus and its subfields in schizophrenia. Am J Psychiatry. 2002; 159:821\u2013828.10.1176\/appi.ajp.159.5.821","DOI":"10.1176\/appi.ajp.159.5.821"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_007_w2aab3b7b8b1b6b1ab1ab7Aa","doi-asserted-by":"crossref","unstructured":"7. Harrison PJ. The hippocampus in schizophrenia: a review of the neuropathological evidence and its pathophysiological implications. Psychopharmacology (Berl). 2004; 174:151\u2013162.10.1007\/s00213-003-1761-y","DOI":"10.1007\/s00213-003-1761-y"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_008_w2aab3b7b8b1b6b1ab1ab8Aa","doi-asserted-by":"crossref","unstructured":"8. Patterson PH. Maternal infection: window on neuroimmune interactions in fetal brain development and mental illness. Curr. Opin. Neurobiol. 2002; 12:115\u2013118.10.1016\/S0959-4388(02)00299-4","DOI":"10.1016\/S0959-4388(02)00299-4"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_009_w2aab3b7b8b1b6b1ab1ab9Aa","doi-asserted-by":"crossref","unstructured":"9. LiuYP, Lin HI, Tzeng SF. Tumor necrosis factor-_and interleukin-18 modulate neuronal cell fate in embryonic neural progenitor culture. Brain Res. 2005; 1054:152\u2013158.10.1016\/j.brainres.2005.06.08516054598","DOI":"10.1016\/j.brainres.2005.06.085"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_010_w2aab3b7b8b1b6b1ab1ac10Aa","doi-asserted-by":"crossref","unstructured":"10. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci. Lett. 1999; 271:126\u2013128.10.1016\/S0304-3940(99)00545-5","DOI":"10.1016\/S0304-3940(99)00545-5"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_011_w2aab3b7b8b1b6b1ab1ac11Aa","doi-asserted-by":"crossref","unstructured":"11. Radewicz K., Garey L J, Gentleman S M, Reynolds R. Increase in HLA-DRimmunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J. Neuropathol. Exp. Neurol. 2000; 59:137\u2013150.10.1093\/jnen\/59.2.137","DOI":"10.1093\/jnen\/59.2.137"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_012_w2aab3b7b8b1b6b1ab1ac12Aa","doi-asserted-by":"crossref","unstructured":"12. Steiner J, Bielau H, Brisch R., Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008;42:151\u201315710.1016\/j.jpsychires.2006.10.01317174336","DOI":"10.1016\/j.jpsychires.2006.10.013"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_013_w2aab3b7b8b1b6b1ab1ac13Aa","unstructured":"13. Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W, Stepien T, Pasennik E. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol. 2005; 43:81\u201389."},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_014_w2aab3b7b8b1b6b1ab1ac14Aa","doi-asserted-by":"crossref","unstructured":"14. Arnold SE, TrojanowskiJQ, Gur R E, Blackwell P, Han LY, Choi C. Absence of neurodegeneration and neural injury in the cerebral cortex in a sample of elderly patients with schizophrenia. Arch. Gen. Psychiatry 1998; 55: 225\u2013232.10.1001\/archpsyc.55.3.225","DOI":"10.1001\/archpsyc.55.3.225"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_015_w2aab3b7b8b1b6b1ab1ac15Aa","doi-asserted-by":"crossref","unstructured":"15. Falke E, HanLY, Arnold SE. Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia. Psychiatry Res. 2000;93:103\u2013110.10.1016\/S0165-1781(00)00104-9","DOI":"10.1016\/S0165-1781(00)00104-9"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_016_w2aab3b7b8b1b6b1ab1ac16Aa","doi-asserted-by":"crossref","unstructured":"16. Togo T, Akiyama H, Kondo H, Ikeda K., Kato M., Iseki E, Kosaka K. Expression of CD40 in the brain of Alzheimer\u2019s disease and other neurological diseases. Brain Res. 2000; 885:117\u2013121.10.1016\/S0006-8993(00)02984-X","DOI":"10.1016\/S0006-8993(00)02984-X"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_017_w2aab3b7b8b1b6b1ab1ac17Aa","doi-asserted-by":"crossref","unstructured":"17. Padmos RC, Hillegers M H, Knijff EM, Vonk R., Bouvy A., Staal FJ, de RidderD, KupkaRW, Nolen WA, DrexhageHA. A discriminating messenger RNA signature for bipolar disorder formed by an aberrant expression of inflammatory genes in monocytes. Arch. Gen. Psychiatry 2008; 65:395\u2013407.10.1001\/archpsyc.65.4.39518391128","DOI":"10.1001\/archpsyc.65.4.395"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_018_w2aab3b7b8b1b6b1ab1ac18Aa","doi-asserted-by":"crossref","unstructured":"18. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav. Immun. 2011; 25:1206\u20131213.10.1016\/j.bbi.2011.03.01321443944","DOI":"10.1016\/j.bbi.2011.03.013"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_019_w2aab3b7b8b1b6b1ab1ac19Aa","doi-asserted-by":"crossref","unstructured":"19. Schulze TG. Genetic research into bipolar disorder: the need for a research framework that integrates sophisticated molecular biology and clinically informed phenotype characterization. Psychiatr Clin North Am. 2010 Mar;33(1):67-82.10.1016\/j.psc.2009.10.005282461720159340","DOI":"10.1016\/j.psc.2009.10.005"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_020_w2aab3b7b8b1b6b1ab1ac20Aa","doi-asserted-by":"crossref","unstructured":"20. Haarman BC, Riemersma-Van der Lek RF, Burger H, Netkova M, Drexhage RC, Bootsman F, Mesman E, Hillegers MH, Spijker AT, Hoencamp E, Drexhage HA, Nolen WA. Relationship between clinical features and inflammation-related monocyte gene expression in bipolar disorder - towards a better understanding of psychoimmunological interactions. Bipolar Disord. 2014 Mar;16(2):137-50.10.1111\/bdi.1214224286609","DOI":"10.1111\/bdi.12142"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_021_w2aab3b7b8b1b6b1ab1ac21Aa","doi-asserted-by":"crossref","unstructured":"21. Benes FM, Matzilevich D, Burke RE, Walsh J. The expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry. 2006 Mar;11(3):241-51.10.1038\/sj.mp.400175816288314","DOI":"10.1038\/sj.mp.4001758"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_022_w2aab3b7b8b1b6b1ab1ac22Aa","doi-asserted-by":"crossref","unstructured":"22. Che Y, Wang JF, Shao L, Young T. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci. 2010 Sep;35(5):296-302.10.1503\/jpn.090083292828220569644","DOI":"10.1503\/jpn.090083"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_023_w2aab3b7b8b1b6b1ab1ac23Aa","doi-asserted-by":"crossref","unstructured":"23. Tian SY, Wang JF, Bezchlibnyk YB, Young LT. Immunoreactivity of 43 kDa growth-associated protein is decreased in post mortem hippocampus of bipolar disorder and schizophrenia. Neurosci Lett. 2007 Jan 10;411(2):123-7.10.1016\/j.neulet.2006.10.03117095155","DOI":"10.1016\/j.neulet.2006.10.031"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_024_w2aab3b7b8b1b6b1ab1ac24Aa","unstructured":"24. Kato N, Nemoto K, Arino H, Fujikawa K. Influence of peripheral inflammation on growth-associated phosphoprotein (GAP-43) expression in dorsal root ganglia and on nerve recovery after crush injury. Neurosci Res. 200310.1016\/S0168-0102(02)00234-1"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_025_w2aab3b7b8b1b6b1ab1ac25Aa","doi-asserted-by":"crossref","unstructured":"25. Savitz J, Frank MB, Victor T, Bebak M, Marino JH, Bellgowan PS, McKinney BA, Bodurka J, Kent Teague T, Drevets WC. Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional imaging abnormalities. Brain Behav Immun. 2013 Jul;31:161-71.10.1016\/j.bbi.2012.10.007","DOI":"10.1016\/j.bbi.2012.10.007"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_026_w2aab3b7b8b1b6b1ab1ac26Aa","doi-asserted-by":"crossref","unstructured":"26. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J. Psychiatry Neurosci. 2009; 34:4\u201320.","DOI":"10.1139\/jpn.0902"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_027_w2aab3b7b8b1b6b1ab1ac27Aa","doi-asserted-by":"crossref","unstructured":"27. Kooij G, van Horssen J, BandaruVV, Haughey NJ, de Vries HE. The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids. Front Pharmacol. 2012 Apr 30;3:74.10.3389\/fphar.2012.00074","DOI":"10.3389\/fphar.2012.00074"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_028_w2aab3b7b8b1b6b1ab1ac28Aa","doi-asserted-by":"crossref","unstructured":"28. Huang YH, Sch\u00e4fer-Elinder L, Wu R, Claesson HE, Frosteg\u00e5rd J. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol. 1999 May;116(2):326-31.10.1046\/j.1365-2249.1999.00871.x","DOI":"10.1046\/j.1365-2249.1999.00871.x"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_029_w2aab3b7b8b1b6b1ab1ac29Aa","doi-asserted-by":"crossref","unstructured":"29. Franke RM, Gardner ER and SparreboomA.Pharmacogenetics of Drug Transporters Current Pharmaceutical Desig. 2010; 16: 220-230.10.2174\/138161210790112683","DOI":"10.2174\/138161210790112683"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_030_w2aab3b7b8b1b6b1ab1ac30Aa","doi-asserted-by":"crossref","unstructured":"30. Zhu Hao-Jie, Wang Jun-Sheng, Markowitz SJ, Donovan LJ, Gibson BB and DeVane CL. Risperidone and Paliperidone Inhibit P-Glycoprotein Activity In Vitro Neuropsychopharmacology. 2007; 32: 757\u2013764.10.1038\/sj.npp.1301181","DOI":"10.1038\/sj.npp.1301181"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_031_w2aab3b7b8b1b6b1ab1ac31Aa","doi-asserted-by":"crossref","unstructured":"31. Tang K, Ngoi SM, Gwee PC, Chua JM, Lee EJ, Chong SS et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 2002; 12: 437\u2013450.10.1097\/00008571-200208000-00004","DOI":"10.1097\/00008571-200208000-00004"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_032_w2aab3b7b8b1b6b1ab1ac32Aa","doi-asserted-by":"crossref","unstructured":"32. Cascorbi I. Role of pharmacogenetics of ATP-binding cassette transporters inthe pharmacokinetics of drugs. Pharmacol Ther. 2006 Nov;112(2):457-73. Review.10.1016\/j.pharmthera.2006.04.009","DOI":"10.1016\/j.pharmthera.2006.04.009"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_033_w2aab3b7b8b1b6b1ab1ac33Aa","doi-asserted-by":"crossref","unstructured":"33. Kimchi-Sarfaty C, Marple AH, Shinar S, Kimchi AM, Scavo D, Roma MI, Kim IW, Jones A, Arora M, Gribar J, Gurwitz D, Gottesman MM. Ethnicity-related polymorphisms and haplotypes in human ABCB1 gene. Pharmacogenomics. 2007;8(1):29-39.10.2217\/14622416.8.1.29","DOI":"10.2217\/14622416.8.1.29"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_034_w2aab3b7b8b1b6b1ab1ac34Aa","doi-asserted-by":"crossref","unstructured":"34. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 2000 Nov;23(5):477-501. Review.10.1016\/S0893-133X(00)00159-7","DOI":"10.1016\/S0893-133X(00)00159-7"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_035_w2aab3b7b8b1b6b1ab1ac35Aa","doi-asserted-by":"crossref","unstructured":"35. Raggers RJ, Vogels I, van Meer G. Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor. Biochem J. 2001 Aug 1;357(Pt 3):859-65.10.1042\/bj3570859","DOI":"10.1042\/bj3570859"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_036_w2aab3b7b8b1b6b1ab1ac36Aa","doi-asserted-by":"crossref","unstructured":"36. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockm\u00f6 ller J, Johne A, et al. Functional polymorphism of the human multidrug-resistance gene: multiple sequence variations and correlations of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000; 97: 3473\u20133478.10.1073\/pnas.97.7.3473","DOI":"10.1073\/pnas.97.7.3473"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_037_w2aab3b7b8b1b6b1ab1ac37Aa","doi-asserted-by":"crossref","unstructured":"37. M\u00fcller MB, Keck ME, Binder EB, Kresse AE, Hagemeyer TP, Landgraf R, Holsboer F, Uhr M. ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary-adrenocortical system: implications for affective disorder. Neuropsychopharmacology. 2003 Nov;28(11):1991-9.10.1038\/sj.npp.1300257","DOI":"10.1038\/sj.npp.1300257"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_038_w2aab3b7b8b1b6b1ab1ac38Aa","doi-asserted-by":"crossref","unstructured":"38. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15(2):97-8.10.1038\/sj.cr.7290272","DOI":"10.1038\/sj.cr.7290272"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_039_w2aab3b7b8b1b6b1ab1ac39Aa","doi-asserted-by":"crossref","unstructured":"39. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, He L, Shi Y. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http:\/\/analysis.bio-x-cn). Cell Res. 2009;19(4):519-23.10.1038\/cr.2009.33","DOI":"10.1038\/cr.2009.33"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_040_w2aab3b7b8b1b6b1ab1ac40Aa","doi-asserted-by":"crossref","unstructured":"40. Bozina N, Kuzman MR, Medved V, Jovanovic N, Sertic J, Hotujac L. Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients. J Psychiatr Res. 2008 Jan;42(2):89-97.10.1016\/j.jpsychires.2006.10.002","DOI":"10.1016\/j.jpsychires.2006.10.002"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_041_w2aab3b7b8b1b6b1ab1ac41Aa","doi-asserted-by":"crossref","unstructured":"41. Qian W, Homma M, Itagaki F, Tachikawa H, Kawanishi Y, Mizukami K, Asada T, Inomata S, Honda K, Ohkohchi N, Kohda Y. MDR1 gene polymorphism in Japanese patients with schizophrenia and mood disorders including depression. Biol Pharm Bull. 2006 Dec;29(12):2446-50.10.1248\/bpb.29.2446","DOI":"10.1248\/bpb.29.2446"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_042_w2aab3b7b8b1b6b1ab1ac42Aa","doi-asserted-by":"crossref","unstructured":"42. Tovilla-Z\u00e1rate CA, Vargas I, Hern\u00e1ndez S, Fres\u00e1n A, Aguilar A, Escamilla R, Saracco R, Palacios J, Camarena B. Association study between the MDR1 gene andclinical characteristics in schizophrenia. Rev Bras Psiquiatr. 2014Sep;36(3):227-32. Epub 2014 Jun 10.10.1590\/1516-4446-2013-1270","DOI":"10.1590\/1516-4446-2013-1270"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_043_w2aab3b7b8b1b6b1ab1ac43Aa","doi-asserted-by":"crossref","unstructured":"43. Borst P, Schinkel AH. Genetic dissection of the function of mammalian P-glycoproteins. Trends Genet. 1997 Jun;13(6):217-22.10.1016\/S0168-9525(97)01112-8","DOI":"10.1016\/S0168-9525(97)01112-8"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_044_w2aab3b7b8b1b6b1ab1ac44Aa","doi-asserted-by":"crossref","unstructured":"44. Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, Ieiri I. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J PharmacolExpTher. 2004 Dec;311(3):1179-87.10.1124\/jpet.104.06972415280437","DOI":"10.1124\/jpet.104.069724"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_045_w2aab3b7b8b1b6b1ab1ac45Aa","doi-asserted-by":"crossref","unstructured":"45. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001 Jun;297(3):1137-43.","DOI":"10.1016\/S0022-3565(24)29643-9"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_046_w2aab3b7b8b1b6b1ab1ac46Aa","doi-asserted-by":"crossref","unstructured":"46. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Schirakawa T, et al. Effect of the mutation (C3435T) et exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002; 71: 297\u2013303.10.1067\/mcp.2002.12205511956513","DOI":"10.1067\/mcp.2002.122055"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_047_w2aab3b7b8b1b6b1ab1ac47Aa","doi-asserted-by":"crossref","unstructured":"47. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuga M, Okumura K (2001). MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18: 1400-1404.10.1023\/A:1012244520615","DOI":"10.1023\/A:1012244520615"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_048_w2aab3b7b8b1b6b1ab1ac48Aa","doi-asserted-by":"crossref","unstructured":"48. Turgut G, Kurt E, Sengul C, Alatas G, Kursunluoglu R, Oral T, Turgut S, Herken H. Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Mol Biol Rep. 2009 Mar;36(3):495-9.10.1007\/s11033-007-9206-z18165917","DOI":"10.1007\/s11033-007-9206-z"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_049_w2aab3b7b8b1b6b1ab1ac49Aa","doi-asserted-by":"crossref","unstructured":"49. Fujii T, Ota M, Hori H, Sasayama D, Hattori K, Teraishi T, Yamamoto N, Hashikura M, Tatsumi M, Higuchi T, Kunugi H. Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population. J Psychiatr Res. 2012 Apr;46(4):555-9.10.1016\/j.jpsychires.2012.01.01222306099","DOI":"10.1016\/j.jpsychires.2012.01.012"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_050_w2aab3b7b8b1b6b1ab1ac50Aa","doi-asserted-by":"crossref","unstructured":"50. Santos M, Carvalho S, Lima L, Nogueira A, Assis J, Mota-Pereira J, Pimentel P, Maia D, Correia D, Gomes S, Cruz A, Medeiros R. Common genetic polymorphisms in the ABCB1 gene are associated with risk of major depressive disorder in male Portuguese individuals. Genet Test Mol Biomarkers. 2014 Jan;18(1):12-9.10.1089\/gtmb.2013.019724200053","DOI":"10.1089\/gtmb.2013.0197"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_051_w2aab3b7b8b1b6b1ab1ac51Aa","doi-asserted-by":"crossref","unstructured":"51. Salama NN, Yang Z, Bui T, Ho RJ. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci. 2006 Oct;95(10):2293-308.10.1002\/jps.2071716883550","DOI":"10.1002\/jps.20717"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_052_w2aab3b7b8b1b6b1ab1ac52Aa","doi-asserted-by":"crossref","unstructured":"52. Brunson KL, Avishai-Eliner S, Hatalski CG, Baram TZ. Neurobiology of the stress response early in life: evolution of a concept and the role of corticotropin releasing hormone. Mol Psychiatry. 2001 Nov;6(6):647-56.10.1038\/sj.mp.4000942310072211673792","DOI":"10.1038\/sj.mp.4000942"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_053_w2aab3b7b8b1b6b1ab1ac53Aa","doi-asserted-by":"crossref","unstructured":"53. Kim RB, Leake BF, Choo EF. et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001; 70: 189\u2013199.10.1067\/mcp.2001.117412","DOI":"10.1067\/mcp.2001.117412"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_054_w2aab3b7b8b1b6b1ab1ac54Aa","unstructured":"54. Troost PW, Lahuis BE, Hermans MH, et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 2007; 27:52\u20135710.1097\/JCP.0b013e31802e68d517224713"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_055_w2aab3b7b8b1b6b1ab1ac55Aa","doi-asserted-by":"crossref","unstructured":"55. Hartz AM, Bauer B. Regulation of ABC transporters at the blood-brain barrier: new targets for CNS therapy. Mol Interv. 2010 Oct;10(5):293-304.10.1124\/mi.10.5.621045243","DOI":"10.1124\/mi.10.5.6"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_056_w2aab3b7b8b1b6b1ab1ac56Aa","doi-asserted-by":"crossref","unstructured":"56. von Wedel-Parlow M, W\u00f6lte P, GallaHJ. Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J Neurochem. 2009;111(1):111-8.10.1111\/j.1471-4159.2009.06305.x19656257","DOI":"10.1111\/j.1471-4159.2009.06305.x"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_057_w2aab3b7b8b1b6b1ab1ac57Aa","doi-asserted-by":"crossref","unstructured":"57. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, AbbasiSH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007; 90:179\u2013185.10.1016\/j.schres.2006.11.01617208413","DOI":"10.1016\/j.schres.2006.11.016"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_058_w2aab3b7b8b1b6b1ab1ac58Aa","doi-asserted-by":"crossref","unstructured":"58. Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002; 159:1029\u20131034.10.1176\/appi.ajp.159.6.1029","DOI":"10.1176\/appi.ajp.159.6.1029"},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_059_w2aab3b7b8b1b6b1ab1ac59Aa","unstructured":"59. Laan W. Anti-Inflammatory Drugs and Psychosis (thesis). University of Utrecht, Utrecht, The Netherlands; 2008."},{"key":"2026071212052248885_j_prilozi-2018-0008_ref_060_w2aab3b7b8b1b6b1ab1ac60Aa","doi-asserted-by":"crossref","unstructured":"60. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry. 2001 Mar 1;49(5):391-404. Review.10.1016\/S0006-3223(00)01088-X","DOI":"10.1016\/S0006-3223(00)01088-X"}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/prilozi\/38\/3\/article-p71.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2018-0008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:31:22Z","timestamp":1783902682000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2018-0008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,1]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,4,16]]},"published-print":{"date-parts":[[2017,12,1]]}},"alternative-id":["10.2478\/prilozi-2018-0008"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2018-0008","relation":{},"ISSN":["1857-8985","1857-9345"],"issn-type":[{"value":"1857-8985","type":"electronic"},{"value":"1857-9345","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12,1]]}}}